AzTrials
AzTrials

Cystic FibrosisPhase 3NCT05076149

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

A Phase 3 study testing VX-121/TEZ/D-IVA, ELX/TEZ/IVA and IVA in people with Cystic Fibrosis, run by Vertex Pharmaceuticals Incorporated at 170 sites in 20 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are homozygous for F508del, heterozygous for F508del and a gating (F/G) or residual function (F/RF) mutation, or have at least 1 other TCR CF transmembrane conductance regulator… Read more about this study

Who is it for?
Ages 12 years and older
Conditions the study is for
Cystic Fibrosis
What is being tested?
VX-121/TEZ/D-IVA, ELX/TEZ/IVA and IVA
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
597 participants
Where
170 sitesin 20 countries
Study dates
27 Oct 2021to 30 Nov 2023
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Participant has one of the following genotypes:
  • Homozygous for F508del;
  • Heterozygous for F508del and a gating (F/G) mutation;
  • Heterozygous for F508del and a residual function (F/RF) mutation;
  • At least 1 other TCR CFTR gene mutation identified as responsive to ELX/TEZ/IVA and no F508del mutation
  • Forced expiratory volume in 1 second (FEV1) value >=40% and <=90% of predicted mean for age, sex, and height for participants currently receiving CFTR protein modulator therapy; FEV1 >=40% and <=80% for participants not currently receiving CFTR protein modulator therapy

Who cannot join

  • History of solid organ or hematological transplantation
  • Hepatic cirrhosis with portal hypertension, moderate hepatic impairment (Child Pugh Score 7 to 9), or severe hepatic impairment (Child Pugh Score 10 to 15)
  • Lung infection with organisms associated with a more rapid decline in pulmonary status
  • Pregnant or breast-feeding females
  • Other protocol defined Inclusion/Exclusion criteria may apply.

Trial locations and contacts

170 sites in 20 countries.

170 sites in 20 countries

United States62 sites

  • Akron Children's Hospital

    Akron, Ohio, 44308

  • Michigan Medicine

    Ann Arbor, Michigan, 48109-5212

  • The Emory Clinic at Chantilly

    Atlanta, Georgia, 30324

  • Children's Hospital of Colorado

    Aurora, Colorado, 80045

  • Billings Clinic

    Billings, Montana, 59101

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35233

  • St. Luke's Cystic Fibrosis Center of Idaho

    Boise, Idaho, 83702

  • Massachusetts General Hospital Cystic Fibrosis Center Clinical Rsearch Center

    Boston, Massachusetts, 02114

  • Boston Children's Hospital

    Boston, Massachusetts, 02115

  • CF Therapeutics Development Center of Western New York

    Buffalo, New York, 14203

  • University of Virginia Health System

    Charlottesville, Virginia, 22908

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois, 60611

  • Northwestern Memorial Hospital

    Chicago, Illinois, 60611

  • Vermont Lung Center

    Colchester, Vermont, 05446

  • Prisma Health Richland Campus

    Columbia, South Carolina, 29203

  • Nationwide Children's Hospital

    Columbus, Ohio, 43205

  • The University of Texas Southwestern Medical Center

    Dallas, Texas, 75390-8558

  • Dayton Children's Hospital

    Dayton, Ohio, 45404

  • National Jewish Health

    Denver, Colorado, 80206

  • Harper University Hospital

    Detroit, Michigan, 48201

  • Cook Children's Health Care System

    Fort Worth, Texas, 76104

  • Spectrum Health Medical Group Adult Cystic Fibrosis Care Center

    Grand Rapids, Michigan, 49546

  • Indiana University

    Indianapolis, Indiana, 46202

  • Riley Hospital for Children at Indiana University Health

    Indianapolis, Indiana, 46202

  • University of Mississippi Medical Center

    Jackson, Mississippi, 39216

  • Nemours Children's Specialty Care

    Jacksonville, Florida, 32207

  • The Children's Mercy Hospital

    Kansas City, Missouri, 64108

  • University of Tennessee Medical Center

    Knoxville, Tennessee, 37920

  • University of Kentucky

    Lexington, Kentucky, 40536

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas, 72205

  • Children's Hospital Los Angeles

    Los Angeles, California, 90027

  • University Hospital and UW Health Clinics

    Madison, Wisconsin, 53792

  • University of Miami Miller School of Medicine

    Miami, Florida, 33136

  • West Virginia University

    Morgantown, West Virginia, 26506

  • Morristown Medical Center

    Morristown, New Jersey, 07960

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232

  • Yale New Haven Hospital

    New Haven, Connecticut, 06510

  • Northwell Health- Long Island Jewish Medical Center

    New Hyde Park, New York, 11040

  • Tulane Medical Center

    New Orleans, Louisiana, 70112

  • Columbia University Medical Center

    New York, New York, 10032

  • Children's Hospital of the King's Daughters

    Norfolk, Virginia, 23507

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, 73104

  • Santiago Reyes, M.D.

    Oklahoma City, Oklahoma, 73112

  • Children's Hospital of Orange County

    Orange, California, 92868

  • Central Florida Pulmonary Group, PA

    Orlando, Florida, 32803

  • Nemours Children's Specialty Care, Pensacola

    Pensacola, Florida, 32514

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania, 15224

  • Maine Medical Partners

    Portland, Maine, 04102

  • Oregon Health & Science University

    Portland, Oregon, 97239

  • University of California Davis Medical Center

    Sacramento, California, 95817

  • University of Utah - Primary Children's Medical Center

    Salt Lake City, Utah, 84132

  • University of Washington Medical Center

    Seattle, Washington, 98195

  • Sanford Children's Speciality Clinic

    Sioux Falls, South Dakota, 57105

  • Providence Pediatric Pulmonary & Cystic Fibrosis Clinic

    Spokane, Washington, 99204

  • Washington University School of Medicine

    St Louis, Missouri, 63110

  • Johns Hopkins All Children's Hospital Outpatient Care Center

    St. Petersburg, Florida, 33701

  • SUNY Upstate Medical University

    Syracuse, New York, 13210

  • ProMedica Toledo Hospital/Toledo Children's Hospital/Pediatric Pulmonary & Cystic Fibrosis Center

    Toledo, Ohio, 43606

  • Banner University of Arizona Medical Center

    Tucson, Arizona, 85724

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina, 27104

  • UMass Memorial Medical Center

    Worcester, Massachusetts, 01655

Other trials in United States

France17 sites

  • Groupe Hospitaler Pellegrin, CHU De Bordeaux

    Bordeaux

  • CHU Lyon - Hopital Femme Mere-Enfant

    Bron

  • Centre Hospitalier Intercommunal Creteil

    Créteil

  • Institut Cœur Poumon, CHU de Lille

    Lille

  • Hopital Arnaud de Villeneuve

    Montpellier

  • Centre Hospitalier Universitaire De Nantes - G. R. Laennec

    Nantes

  • Centre Hospitalier Universitaire (CHU) de Nice - Hopital Pasteur

    Nice

  • Hopital Cochin

    Paris

  • Hopital Necker, Enfants Malades

    Paris

  • Hopital Robert Debre

    Paris

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite

  • Centre de Perharidy

    Roscoff

  • CHU de Rouen - Hopital Charles Nicolle

    Rouen Cedex, Seine Maritime

  • Hôpital de Hautepierre, AX5

    Strasbourg

  • Hopital Foch (Suresnes), Hopital Foch, Adultes

    Suresnes

  • Hopital Bretonneau

    Tours

  • Centre hospitalier universitaire de Nancy, Hôpital de Braboi

    Vandœuvre-lès-Nancy

Other trials in France

United Kingdom12 sites

  • Birmingham Children's Hospital

    Birmingham

  • Royal Papworth Hospital NHS Foundation Trust

    Cambridge

  • Clinical Research Facility, Queen Elizabeth University Hospital

    Glasgow

  • Leeds General Infirmary

    Leeds

  • St. James University Hospital

    Leeds

  • King's College Hospital

    London

  • Royal Brompton Hospital

    London

  • St. Bartholomew's Hospital

    London

  • Royal Manchester Children's Hospital

    Manchester

  • Wythenshawe Hospital

    Manchester

  • All Wales Adult Cystic Fibrosis Centre, University Hospital Llandough

    Penarth

  • Southampton General Hospital

    Southampton

Other trials in United Kingdom

Australia10 sites

  • Royal Prince Alfred Hospital

    Camperdown

  • The Prince Charles Hospital

    Chermside

  • Alfred Hospital

    Melbourne, VIC

  • Institute for Respiratory Health

    Nedlands

  • Telethon Kids Institute

    Nedlands

  • The Royal Children's Hospital

    Parkville, VIC

  • Sydney Children's Hospital

    Randwick

  • Mater Adult Hospital

    South Brisbane

  • Queensland Children's Hospital

    South Brisbane

  • Westmead Hospital

    Westmead

Other trials in Australia

Canada9 sites

  • University of Calgary Medical Clinic of the Foothills Medical Centre

    Calgary

  • Stollery Children's Hospital

    Edmonton

  • St. Joseph's Health Care London

    London

  • Centre Hospitalier de l'Universite de Montreal (CHUM) Hotel-Dieu

    Montreal

  • McGill University Health Centre, Glen Site, Montreal Children's Hospital

    Montreal

  • Institut Universitaire de Cardiologie et Pneumologie de Quebec - Universite Laval

    Québec

  • St. Michael's Hospital

    Toronto

  • British Columbia Children's Hospital

    Vancouver

  • St. Paul's Hospital

    Vancouver

Other trials in Canada

Italy8 sites

  • Azienda Ospedaliero Universitaria Ospedale Riuniti

    Ancona

  • Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer

    Florence

  • IRCCS Istituto Giannina Gaslini-Ospedale Pediatrico

    Genova

  • Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena

    Milan

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

    Milan

  • Malattie Apparato Respiratorio 2 - Centro Fibrosi Cistica

    Orbassano

  • Centro Regionale Fibrosi Cistica, A.O. Ospedale San Carlo

    Potenza

  • Azienda Ospedaliera di Verona - Ospedale Civile Maggiore

    Verona

Other trials in Italy

Ireland7 sites

  • Cork University Hospital

    Cork

  • Children's Health Ireland at Crumlin

    Dublin

  • Children's Health Ireland at Tallaght

    Dublin

  • Children's University Hospital, Dublin

    Dublin

  • St. Vincent's University Hospital

    Dublin

  • University Hospital Limerick (Adults)

    Limerick

  • University Hospital Limerick (Pediatrics)

    Limerick

Other trials in Ireland

Germany6 sites

  • Charite Paediatric Pulmonology Department

    Berlin

  • Friedrich-Alexander University of Erlangen-Nuremberg, University Children's Hospital

    Erlangen

  • Ruhrlandklinik Westdeutsches Lungenzentrum am Klinikum Essen

    Essen

  • Universitatsklinikum Essen (AoR), Kinderklinik III, Abt. fur Pneumologie

    Essen

  • Justus-Liebig-Universität Gießen Zentrum für Kinderheilkunde und Jugendmedizin

    Giessen

  • Pneumologisches Studienzentrum Muenchen-West

    München

Other trials in Germany

Austria5 sites

  • University of Graz

    Graz

  • Medizinische Universität Innsbruck

    Innsbruck

  • Uniklinikum Salzburg - Universitätsklinik für Pneumologie/Lungenheilkunde

    Salzburg

  • Medizinische Universität Wien

    Vienna

  • Abteilung fuer Pulmologie Klinikum Wels-Grieskirchen

    Wels

Other trials in Austria

Belgium5 sites

  • Cliniques Universitaires de Bruxelles Hopital Erasme

    Brussels

  • Universitair Ziekenhuis Brussel - Campus Jette

    Brussels

  • Universitair Ziekenhuis Gent

    Ghent

  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

    Leuven

  • Cliniques Universitaires Saint-Luc

    Woluwe-Saint-Lambert

Other trials in Belgium

Netherlands5 sites

  • Academisch Medisch Centrum (Academic Medical Centre)

    Amsterdam

  • UMC St. Radboud

    Nijmegen

  • Erasmus Medical Center

    Rotterdam

  • HagaZiekenhuis van den Haag

    The Hague

  • University Medical Center, Utrecht, Department of Pulmonology and Tuberculosis

    Utrecht

Other trials in Netherlands

New Zealand4 sites

  • Greenlane Clinical Centre

    Auckland

  • Starship Children's Hospital

    Auckland

  • Canterbury Respiratory Research Group

    Christchurch Hospital

  • Waikato Hospital

    Hamilton

Other trials in New Zealand

Israel3 sites

  • Hadassah Medical Organization

    Jerusalem

  • Schneider Children's Medical Center of Israel

    Petach Tikvah

  • Sheba Medical Center - The Edmond and Lili Safra Children's Hospital

    Tel HaShomer

Other trials in Israel

Poland3 sites

  • Pediatric Hospital Polanki named of Maciej Płażyński

    Gdansk

  • Klinika Mukowiscydozy IMD Oddozial Chorob Pluc Szpzoz IM. Dzieci WarszaWY

    Łomianki

  • Institute of Tuberculosis and Lung Diseases

    Rabka-Zdrój

Other trials in Poland

Sweden3 sites

  • Sahlgrenska Universitetssjukhuset

    Gothenburg

  • Lund University Skanes Universitetssjukhus

    Malmö

  • Karolinska Universitetssjukhuset, Huddinge

    Stockholm

Other trials in Sweden

Switzerland3 sites

  • Lindenhofspital - Quartier Bleu

    Bern

  • Réseau Hospitalier Neuchâtelois

    Neuchâtel

  • Kinderspital Zuerich

    Zurich

Other trials in Switzerland

Denmark2 sites

  • Aarhus University Hospital

    Aarhus

  • Juliane Marie Center, Rigshospitalet

    Copenhagen

Other trials in Denmark

Greece2 sites

  • General Hospital of Thessaloniki "Papanikolaou"

    Pilea Chortiatis

  • General Hospital of Thessaloniki 'Hippokratio', 3rd Pediatrics Department of Aristotle University of Thessaloniki

    Thessaloniki

Other trials in Greece

Hungary2 sites

  • National Koranyi Institute for TBC and Pulmonology

    Budapest

  • Pulmonology Institute Torokbalint

    Törökbálint

Other trials in Hungary

Norway2 sites

  • Haukeland Universitetssjukehus (CF)

    Bergen

  • Oslo University Hospital, Department of Paediatric Medicine

    Oslo

Other trials in Norway

About this study

Official title: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation

The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are homozygous for F508del, heterozygous for F508del and a gating (F/G) or residual function (F/RF) mutation, or have at least 1 other TCR CF transmembrane conductance regulator (CFTR) gene mutation and no F508del mutation.

Conditions
Cystic Fibrosis
Being tested
VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, Placebo (matched to VX-121/TEZ/D-IVA), Placebo (matched to ELX/TEZ/IVA)
Medical subject headings
Cystic Fibrosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VX-121/TEZ/D-IVADrug

    Also called VX-121/VX-661/CTP-656, VX-121/VX-661/VX-561, VX-121/tezacaftor/deutivacaftor

    Fixed-dose combination tablets for oral administration.

  • ELX/TEZ/IVADrug

    Also called VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor

    Fixed-dose combination tablets for oral administration.

  • IVADrug

    Also called VX-770, ivacaftor

    Tablet for oral administration.

  • Placebo (matched to VX-121/TEZ/D-IVA)Drug

    Placebo matched to VX-121/TEZ/D-IVA for oral administration.

  • Placebo (matched to ELX/TEZ/IVA)Drug

    Placebo matched to ELX/TEZ/IVA for oral administration.

  • Placebo (matched to IVA)Drug

    Placebo matched to IVA for oral administration.

Study groups in NCT05076149
Study groupRoleWhat they receive
ELX/TEZ/IVAActive comparatorFollowing elexacftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) run-in period of 4 weeks, participants received ELX 200 milligram (mg) once daily (qd) /TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period for 52 weeks.
Receives: Drug: ELX/TEZ/IVA; Drug: IVA; Drug: Placebo (matched to VX-121/TEZ/D-IVA)
VX-121/TEZ/D-IVAExperimentalFollowing ELX/TEZ/IVA run-in period of 4 weeks, participants received VX-121 20 mg qd/TEZ 100 mg qd/D-IVA 250 mg qd in the treatment period for 52 weeks.
Receives: Drug: VX-121/TEZ/D-IVA; Drug: Placebo (matched to ELX/TEZ/IVA); Drug: Placebo (matched to IVA)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Absolute Change in Percent Predicted Forced Expiratory Volume in 1second (ppFEV1)

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Measured: From Baseline Through Week 24

Secondary outcomes (3)

  1. Absolute Change in Sweat Chloride (SwCl)

    Sweat samples were collected using an approved collection device.

    Measured: From Baseline Through Week 24

  2. Percentage of Participants With SwCl <60 Millimole Per Liter (mmol/L) (Pooled With Data From Study VX20-121-102)

    Sweat samples were collected using an approved collection device.

    Measured: From Baseline Through Week 24

  3. Percentage of Participants With SwCl <30 mmol/L (Pooled With Data From Study VX20-121-102)

    Sweat samples were collected using an approved collection device.

    Measured: From Baseline Through Week 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Oct 2021
  2. Study start27 Oct 2021
  3. Primary completion18 May 2023
  4. Study completion30 Nov 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
597 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05076149
Sponsor's protocol ID
VX20-121-103
Other IDs
2021-000694-85
Status last verified
May 2024
First submitted
29 Sep 2021
Last updated
13 Jun 2024
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No: Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

Publications

  • Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A; VX20-121-102 Study Group; VX20-121-103 Study Group. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med. 2025 Mar;13(3):256-271. doi: 10.1016/S2213-2600(24)00411-9. Epub 2025 Jan 2.

    PubMed 39756424

  • Heneghan M, Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2023 Nov 20;11(11):CD010966. doi: 10.1002/14651858.CD010966.pub4.

    PubMed 37983082

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing VX-121/TEZ/D-IVA, ELX/TEZ/IVA and IVA in people with Cystic Fibrosis, run by Vertex Pharmaceuticals Incorporated at 170 sites in 20 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 170 sites in United States, France, United Kingdom, Australia, Canada and 15 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 13 Jun 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Absolute Change in Percent Predicted Forced Expiratory Volume in 1second (ppFEV1) (time frame: From Baseline Through Week 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05076149, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jun 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in